Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Pacira Pharmaceuticals ( (PCRX) ).
On July 3, 2025, Pacira BioSciences, Inc. entered into a new credit agreement with Wells Fargo Bank and other lenders to refinance its existing credit agreement and provide ongoing working capital. The agreement includes a $300 million senior secured revolving credit facility, with a maturity date of July 3, 2030, and is secured by the company’s and its subsidiaries’ assets. The company used part of this facility to repay its previous credit agreement without incurring prepayment penalties, potentially enhancing its financial flexibility and operational capacity.
The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.
Spark’s Take on PCRX Stock
According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.
Pacira’s overall stock score of 59 reflects solid strategic progress and positive sentiment from its earnings call, which is offset by challenges in profitability and bearish technical indicators. Significant efforts in growth and innovation are promising, but financial stability needs improvement.
To see Spark’s full report on PCRX stock, click here.
More about Pacira Pharmaceuticals
Pacira BioSciences, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative pain management and regenerative health solutions.
Average Trading Volume: 814,404
Technical Sentiment Signal: Sell
Current Market Cap: $1.08B
See more insights into PCRX stock on TipRanks’ Stock Analysis page.